Liver Disease Treatment — Cost, Top Hospitals & Success Rates | MyMedicPlus

The liver performs over 500 distinct metabolic functions including synthesis of proteins (albumin, clotting factors), detoxification of drugs and toxins, bile production for fat digestion, glycogen storage, and immune surveillance. Liver disease encompasses a broad spectrum of conditions ranging from acute, self-limiting injury to progressive chronic disease culminating in cirrhosis, liver failure, and hepatocellular carcinoma.

Liver disease is classified by aetiology (cause), chronology (acute vs chronic), and severity (mild to end-stage). Major aetiological categories include: viral hepatitis (hepatitis A, B, C, D, and E viruses); metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD/NASH), now the most prevalent liver disease globally with an estimated 1.5 billion people affected; alcohol-related liver disease (ArLD); autoimmune liver diseases (autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis); genetic and metabolic disorders (hereditary haemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency); and drug-induced liver injury (DILI).

Liver disease globally accounts for approximately 2 million deaths annually — 1 million from cirrhosis complications and 1 million from viral hepatitis and hepatocellular carcinoma. The availability of curative HCV direct-acting antivirals (DAAs), effective HBV antiviral therapy, and the first disease-modifying therapy for MASH (metabolic dysfunction-associated steatohepatitis — resmetirom, approved by the FDA in March 2024) represent landmark advances in hepatology over the past decade.

Diagnosis of the underlying aetiology is essential before initiating treatment, as management strategies differ radically between conditions. Initial evaluation includes serological testing for viral hepatitis markers (HBsAg, anti-HCV, HAV IgM, HEV IgG/IgM), autoimmune markers (ANA, ASMA, AMA, anti-LKM1), metabolic assessment (serum ferritin, transferrin saturation, ceruloplasmin, alpha-1 antitrypsin level and phenotype), and imaging (liver ultrasound with elastography for fibrosis staging). Liver biopsy, though increasingly replaced by non-invasive fibrosis assessment tools (FIB-4 index, liver stiffness on transient elastography), remains the gold standard for staging fibrosis and diagnosing specific conditions (AIH, storage diseases).

Hepatitis A (HAV): HAV causes acute, self-limiting hepatitis transmitted by the faecal-oral route. There is no specific antiviral treatment for HAV infection; management is supportive (rest, adequate hydration, avoidance of hepatotoxic drugs and alcohol). Fulminant HAV hepatic failure occurs in fewer than 1% of cases but requires intensive care and liver transplant evaluation. The inactivated HAV vaccine provides near-complete protection and is recommended for travellers to endemic areas, household contacts of infected individuals, and persons with chronic liver disease.

Hepatitis B (HBV): Chronic HBV (HBsAg positive for over 6 months) is treated to suppress viral replication, prevent cirrhosis and HCC, and reduce transmission risk. First-line antiviral agents are tenofovir alafenamide (TAF) 25 mg/day (preferred for patients with renal or bone disease) and entecavir 0.5 mg/day (1 mg in lamivudine-experienced patients). Both suppress HBV DNA to undetectable levels in over 95% of patients within 48 weeks. Treatment is lifelong in most patients with established cirrhosis. Hepatitis B surface antigen (HBsAg) loss (functional cure) occurs in fewer than 5% per year on oral antivirals but is the aspirational endpoint of treatment. Pegylated interferon-alpha 180 mcg weekly for 48 weeks achieves HBsAg loss in 3-7% and is considered for young patients with HBeAg-positive infection who wish to avoid indefinite therapy.

Hepatitis C (HCV): HCV is the first chronic viral infection to be curable with oral antiviral therapy. Pan-genotypic direct-acting antiviral (DAA) regimens including sofosbuvir/velpatasvir (Epclusa, 12 weeks) and glecaprevir/pibrentasvir (Mavyret/Maviret, 8-12 weeks) achieve sustained virological response (SVR, defined as undetectable HCV RNA at 12 weeks post-treatment, equivalent to cure) in over 95% of patients regardless of genotype, prior treatment history, or cirrhosis status. SVR reduces liver-related mortality by approximately 50% and HCC risk by 70-80%, even in patients with established cirrhosis. HCV treatment is recommended for all chronically infected patients without contraindications, with the WHO target of eliminating HCV as a public health threat by 2030.

Hepatitis D (HDV): HDV is a defective RNA virus that can only infect cells already infected with HBV (requiring HBsAg as its envelope protein). Chronic HDV (hepatitis delta) causes rapidly progressive cirrhosis with a 5-year cirrhosis rate of 40-60%, much higher than HBV monoinfection. Pegylated interferon-alpha (PEG-IFN) is the only established treatment, achieving HDV RNA suppression in approximately 25-30% of patients at 1 year, with frequent relapse. Bulevirtide (Hepcludex), an entry inhibitor blocking sodium/taurocholate co-transporting polypeptide (NTCP), received conditional approval in the EU in 2020 and demonstrated superior HDV RNA suppression compared with PEG-IFN in the MYR301 phase 3 trial. HBV vaccination prevents HDV infection in HBV-naive individuals.

Hepatitis E (HEV): HEV is the most common cause of acute viral hepatitis worldwide. Genotypes 1 and 2 are enterically transmitted and cause epidemic hepatitis in Asia and Africa; genotypes 3 and 4 are zoonotic (pig reservoir) and cause sporadic infections in developed countries. Most acute HEV infections are self-limiting; however, HEV causes disproportionately severe disease in pregnant women (20-25% mortality in third-trimester HEV genotype 1 infection due to fulminant hepatic failure) and can cause chronic progressive hepatitis in immunocompromised patients (organ transplant recipients, haematology patients). Ribavirin is effective for chronic HEV in immunocompromised patients and for acute severe HEV during pregnancy. The recombinant HEV vaccine (Hecolin) is approved in China.

MASLD/NAFLD: MASLD (metabolic dysfunction-associated steatotic liver disease) encompasses a spectrum from simple steatosis (excess fat in over 5% of hepatocytes) to MASH (steatohepatitis with inflammation and hepatocyte ballooning) to MASH-related fibrosis and cirrhosis. Treatment is stratified by disease severity assessed using non-invasive markers (FIB-4 index, liver elastography) or liver biopsy (NAFLD Activity Score).

Patients with simple steatosis or MASLD without significant fibrosis (F0-F1) are managed primarily with lifestyle interventions — weight loss of 7-10% body weight improves all histological components of MASH in over 60% of patients. Pharmacological therapy with resmetirom (Rezdiffra, thyroid hormone receptor-beta agonist) was approved by the FDA in March 2024 for adults with MASH and moderate-to-advanced fibrosis (F2-F3), based on the MAESTRO-NASH trial demonstrating MASH resolution in 26% versus 10% (placebo) and fibrosis improvement by at least one stage in 24% versus 14% at 52 weeks. GLP-1 receptor agonists (semaglutide, liraglutide) improve MASH histology and promote weight loss and are under active investigation; the LEAN trial demonstrated MASH resolution in 59% of semaglutide-treated patients versus 17% on placebo.

Autoimmune Hepatitis (AIH): AIH is indicated for treatment in all patients with interface hepatitis on biopsy or serum AST/ALT above 3 times the upper limit of normal. First-line standard treatment is prednisolone 0.5-1 mg/kg/day (maximum 60 mg/day) with tapering over 4-8 weeks plus azathioprine 1-2 mg/kg/day (introduced after biopsy to confirm the diagnosis and assess tolerance). Over 85% of patients achieve biochemical remission within 12 months. Budesonide 9 mg/day (as an alternative to prednisolone in non-cirrhotic patients) achieves remission with fewer systemic corticosteroid side effects due to high first-pass hepatic metabolism.

Primary Biliary Cholangitis (PBC): All patients with PBC (elevated ALP, positive AMA-M2) should receive ursodeoxycholic acid (UDCA) 13-15 mg/kg/day regardless of liver biopsy stage, as UDCA improves liver biochemistry, delays progression to cirrhosis, and reduces the need for liver transplantation in long-term trials. Approximately 40% of patients have an inadequate biochemical response to UDCA (defined by the Paris-II criteria as ALP greater than 1.5 times ULN, AST greater than 1.5 times ULN, or total bilirubin above 1 mg/dL after 12 months of UDCA). Inadequate responders are offered obeticholic acid (OCA) 5-10 mg/day, a farnesoid X receptor (FXR) agonist, or bezafibrate 400 mg/day (fibrate which reduces ALP and has anti-fibrotic properties in PBC).

Alcohol-Related Liver Disease (ArLD): Complete and sustained alcohol abstinence is the most impactful intervention at all stages of ArLD. Even in advanced cirrhosis, abstinence can improve Child-Pugh and MELD scores and reduce hepatic decompensation risk. Pharmacological support for alcohol use disorder includes naltrexone (opioid antagonist reducing craving — avoid in hepatic decompensation), acamprosate (glutamate modulator), and baclofen (GABA-B agonist — uniquely studied in patients with advanced liver disease, including cirrhosis).

Acute alcohol-related hepatitis (AH) is a distinct clinical syndrome of rapid-onset jaundice, hepatomegaly, and systemic inflammation in the setting of heavy alcohol use. Severity is assessed using the Maddrey discriminant function (MDF = 4.6 x (PT patient - PT control) + serum bilirubin mg/dL). Severe AH (MDF above 32) carries a 30-day mortality of 30-50%. Prednisolone 40 mg/day for 28 days reduces 28-day mortality in severe AH (Mathurin 2011 meta-analysis NNT approximately 5), but the benefit is not sustained at 90 days or 6 months. The Lille score, calculated on day 7 using pre- and post-treatment serum bilirubin, identifies non-responders (Lille score above 0.45) in whom prednisolone provides no benefit and increases infection risk; prednisolone should be discontinued in non-responders. N-acetylcysteine added to prednisolone (Nguyen-Khac 2011 trial) improved 30-day but not 6-month survival, and is used by some centres as adjunct therapy. Pentoxifylline 400 mg three times daily, formerly used for AH, did not reduce mortality in the large STOPAH trial (NEJM 2015) and is no longer recommended.

Primary Sclerosing Cholangitis (PSC): PSC is a chronic cholestatic liver disease characterised by progressive fibrous obliteration of bile ducts leading to biliary cirrhosis, cholangiocarcinoma (10-15% lifetime risk), and need for liver transplantation. Unlike PBC, there is no approved pharmacological therapy that alters the natural history of PSC. Ursodiol (UDCA) at high dose (28-30 mg/kg/day) was associated with harm (increased risk of colorectal neoplasia and transplant or death) in a randomised trial and is not recommended. Standard-dose UDCA (15-20 mg/kg/day) reduces liver biochemistry but has not been shown to improve survival and is used selectively. The primary treatment for dominant bile duct strictures is endoscopic retrograde cholangiopancreatography (ERCP) with biliary dilation and stenting. All PSC patients should undergo regular colonoscopy surveillance for colorectal cancer (annual in PSC-IBD), CA 19-9 monitoring, and cholangiography (MRCP or ERCP) for CCA surveillance. Liver transplantation is the only effective treatment for PSC-related end-stage liver disease and CCA (in highly selected patients meeting criteria).

Drug-Induced Liver Injury (DILI): The cornerstone of DILI management is prompt identification and discontinuation of the offending agent. DILI accounts for over 50% of cases of acute liver failure in Western countries, with paracetamol (acetaminophen) overdose the most common cause. N-acetylcysteine (NAC) is the antidote for paracetamol hepatotoxicity, effective when started within 10-24 hours of ingestion. For non-paracetamol DILI with jaundice (Hy's Law case — drug-induced hepatocellular injury with jaundice carries a mortality of 10-50% without transplantation), the offending drug must be stopped immediately; corticosteroids may be used for immune-mediated DILI with a hypersensitivity pattern. Most DILI cases (non-paracetamol, non-jaundice) resolve within weeks to months of drug discontinuation.

Hereditary Haemochromatosis (HH): HFE gene mutation (C282Y homozygosity) is the most common cause. Treatment is therapeutic phlebotomy (venesection) — removal of 450 mL blood (equivalent to 200-250 mg iron) weekly until serum ferritin falls below 50 microg/L, then maintenance phlebotomy 2-4 times per year. Phlebotomy is safe, effective, and inexpensive; it reverses fatigue, arthralgia, and hepatic fibrosis at early stages but does not reverse cirrhosis.

Wilson Disease: Caused by ATP7B mutations impairing hepatic copper export. First-line treatment in non-cirrhotic patients is oral chelation with D-penicillamine 1-1.5 g/day (divided doses) or trientine (preferred due to better tolerability). Maintenance therapy and zinc acetate 50 mg three times daily (blocks intestinal copper absorption) are used for asymptomatic carriers and maintenance. Acute liver failure in Wilson disease requires emergency liver transplantation as chelation is insufficient in fulminant presentation.

The treatment landscape for liver disease has been transformed over the past decade, with multiple conditions now treatable or curable.

HCV eradication with DAAs provides functional cure in over 95% of patients after an 8-12 week oral course. SVR eliminates the virus permanently, halts the progression of liver fibrosis (and reverses it in F1-F3 fibrosis in the majority of patients), reduces 10-year mortality from liver disease by approximately 50%, and reduces HCC risk by 70-80% even in established cirrhosis. The WHO elimination targets (90% reduction in new cases, 80% reduction in HCV-related mortality by 2030) are achievable globally with DAA access.

HBV antiviral therapy with TAF or entecavir suppresses viral replication in over 95% of patients, reduces hepatic inflammation and progressive fibrosis, and reduces HCC incidence by approximately 50-70% in long-term studies. Functional cure (HBsAg loss) remains rare with current oral antivirals but is the focus of next-generation covalently closed circular DNA (cccDNA) targeting strategies in late-stage clinical trials.

For MASLD/MASH, weight loss of 7-10% resolves MASH histology in approximately 40-60% of patients. Bariatric surgery (sleeve gastrectomy, Roux-en-Y gastric bypass) achieves MASH resolution in 80-90% with F1-F2 fibrosis regression in 45% at 5 years, and is the most effective MASH intervention in morbidly obese patients. Resmetirom (Rezdiffra), the first FDA-approved therapy specifically for MASH with fibrosis, demonstrated histological response in approximately one-quarter of treated patients at 52 weeks and is well-tolerated.

For autoimmune hepatitis, over 85% of patients achieve biochemical and histological remission with prednisolone plus azathioprine. Long-term outcomes are excellent in responders, with near-normal life expectancy when maintenance therapy is continued indefinitely (relapse occurs in over 80% of patients who discontinue therapy).

For primary biliary cholangitis, patients with an adequate biochemical response to UDCA have near-normal life expectancy. Obeticholic acid provides additional ALP reduction in UDCA inadequate responders, reducing the risk of liver disease progression in long-term follow-up data.

HBV antivirals: Tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) are safe and well-tolerated. TDF carries a risk of renal tubular toxicity (Fanconi syndrome) and reduced bone mineral density with prolonged use; TAF was developed to address these concerns and is preferred in patients with pre-existing renal disease, osteoporosis, or older age. Entecavir is also safe but requires dose reduction in renal impairment. HBV antiviral therapy should never be stopped without specialist guidance due to risk of severe HBV reactivation flare with jaundice and liver failure.

HCV DAAs: Sofosbuvir/velpatasvir and glecaprevir/pibrentasvir are remarkably well-tolerated. Headache, fatigue, and nausea affect approximately 10-20% of patients. Important drug interactions exist: sofosbuvir-containing regimens are contraindicated with amiodarone (risk of severe bradycardia). Glecaprevir/pibrentasvir is contraindicated with prior NS5A resistance-associated substitutions and requires dose adjustment for rifampicin (contraindicated) and carbamazepine.

Prednisolone for AIH or AH: Long-term corticosteroid use carries risks of osteoporosis, glucose intolerance/new-onset diabetes, hypertension, cataracts, weight gain, and adrenal suppression. Bone protection with calcium, vitamin D, and bisphosphonates is recommended for patients on long-term prednisolone. Azathioprine requires monitoring for myelosuppression (full blood count monthly for 3 months, then every 3 months).

Obeticholic acid: The most common adverse effect is pruritus (generalised itching), occurring in up to 68% of patients, which is dose-dependent and managed with antihistamines, colestyramine, or dose reduction. Dyslipidaemia (reduced HDL, increased LDL) has been reported with OCA and requires monitoring. An FDA warning was issued in 2018 regarding OCA use in decompensated cirrhosis and Child-Pugh B/C patients, where it can worsen liver function.

Resmetirom: The most common adverse effects are nausea, diarrhoea, and liver enzyme elevations (transaminase increases in approximately 5-6% of patients). No cardiovascular safety signals have emerged in MAESTRO-NASH phase 3 data. Resmetirom interacts with the bile acid transporter and is not recommended with concurrent OATP inhibitors.

Monitoring requirements vary by liver disease type and treatment phase.

For HCV DAA therapy: HCV RNA is checked at week 4 (to confirm viral suppression during therapy), at end of treatment (EOT), and at 12 weeks post-EOT (to confirm SVR12). SVR12 is considered equivalent to virological cure. Annual liver ultrasound and AFP every 6 months should continue indefinitely for patients with pre-treatment cirrhosis (HCC risk persists after cure, though it is reduced).

For HBV antiviral therapy: Monitoring includes HBV DNA (every 3-6 months during first year, every 6-12 months once suppressed), HBeAg/anti-HBe (annually in HBeAg-positive patients to detect seroconversion), HBsAg quantification, ALT, renal function, and bone density (for patients on TDF). Liver elastography every 1-2 years assesses fibrosis regression.

For MASLD/MASH on resmetirom: Liver biochemistry (AST, ALT, ALP), lipid profile, and clinical assessment of weight, BMI, and waist circumference are monitored every 12 weeks during the first 6 months and 6-monthly thereafter. Non-invasive fibrosis assessment (FIB-4, liver elastography) is used to monitor disease trajectory without repeat liver biopsy.

For AIH on azathioprine: Liver function tests and full blood count (for azathioprine myelosuppression) every 1-3 months during induction, then every 3-6 months during maintenance. Thiopurine methyltransferase (TPMT) genotyping or enzyme activity should be checked before azathioprine initiation to identify poor metabolisers at risk of severe myelosuppression.

For PBC on UDCA: ALP, AST, bilirubin, and GGT at 6 months after UDCA initiation (to assess biochemical response), then annually. Pruritus assessment, bone density (DEXA scan) for osteoporosis monitoring (common in PBC), and fat-soluble vitamin levels (A, D, E, K) are included in annual review. Upper GI endoscopy to screen for varices is required in patients with advanced fibrosis.

All patients with liver disease of any aetiology and established cirrhosis require 6-monthly liver ultrasound and AFP for HCC surveillance and annual metabolic review.

Treatment costs for liver disease vary enormously by aetiology, location, and healthcare system.

HCV direct-acting antivirals represent one of the most significant pricing controversies in modern medicine. Sofosbuvir/velpatasvir (Epclusa) and glecaprevir/pibrentasvir (Mavyret) are priced at USD 24,000-75,000 per course in the United States at list price, though negotiated prices with payers are often substantially lower. In India, generic pan-genotypic DAAs (sofosbuvir/velpatasvir) are available for approximately USD 200-400 per 12-week course — 99% cheaper than US list price — thanks to voluntary licensing agreements. The Medicines Patent Pool (MPP) and WHO prequalification of generic DAAs have made HCV treatment accessible in low- and middle-income countries at USD 60-200 per course.

HBV antivirals (tenofovir alafenamide, entecavir) are available as inexpensive generics globally, with generic TAF available in high-burden countries for approximately USD 3-10 per month through licensing agreements, making lifelong HBV treatment financially feasible in most settings.

Resmetirom (Rezdiffra) for MASH was priced at USD 47,400 per year at launch in the United States. Insurance coverage varies and prior authorisation requirements (documented MASH on biopsy with F2-F3 fibrosis) are common. Resmetirom is not yet approved in Europe or most other regions as of 2026.

For patients in lower-resource settings, lifestyle intervention (dietary modification, increased physical activity for MASLD), alcohol abstinence for ArLD, and surveillance are the most cost-effective liver disease management strategies, with demonstrated mortality reductions achieved without pharmacological costs.

Liver disease treatment is advancing rapidly across all aetiological categories.

HBV cure strategies: Several next-generation HBV therapies targeting the viral life cycle beyond viral suppression are in late-stage trials, aiming for functional cure (HBsAg loss). RNA interference (RNAi) agents (siRNA) targeting HBsAg messenger RNA — including JNJ-3989 (bepirovirsen, GSK) and VIR-2218 — have demonstrated significant HBsAg reduction in phase 2 trials. Combination strategies with RNAi plus PEG-IFN or novel entry inhibitors are under phase 3 investigation.

MASLD/MASH pipeline: Following resmetirom approval, multiple agents are in phase 3 trials. Lanifibranor (pan-PPAR agonist) improved MASH resolution by 20% over placebo (NATIVE trial). Semaglutide (GLP-1 agonist, ESSENCE trial) showed MASH resolution in 62% versus 34% placebo at 72 weeks in a recent phase 3 interim analysis. Combination approaches targeting multiple MASH pathways simultaneously (e.g., GLP-1 agonist plus FXR agonist) are actively studied.

AIH beyond prednisolone/azathioprine: Mycophenolate mofetil (MMF) 1-1.5 g twice daily is the established second-line immunosuppressant for patients intolerant of or refractory to azathioprine. Tacrolimus (calcineurin inhibitor) is used at specialist centres for truly refractory AIH. Budesonide plus MMF as induction is studied as an alternative to prednisolone for initial therapy in non-cirrhotic AIH.

PBC: The pipeline beyond OCA and bezafibrate includes seladelpar (PPAR-delta agonist) and elafibranor (dual PPAR-alpha/delta agonist), which demonstrated improvements in ALP and pruritus in phase 3 trials and received regulatory review in 2024. Linerixibat (IBAT inhibitor) reduces pruritus in PBC independently of UDCA response.

Liver support for bridging to transplant: The FULMAR trial is evaluating MARS albumin dialysis for acute-on-chronic liver failure as a bridge to transplantation. Bioartificial liver devices incorporating porcine hepatocytes (HepatAssist, ELAD system) have shown variable results in phase 3 trials and are not yet in routine clinical use.